Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.
Gloria Dalla CostaLetizia LeocaniXavier MontalbanAna Isabel GuerreroPer Soelberg SørensenMelinda MagyariRichard J B DobsonNicholas CumminsVaibhav A NarayanMatthew HotopfGiancarlo Cominull nullPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)
We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.
Keyphrases
- multiple sclerosis
- end stage renal disease
- coronavirus disease
- sars cov
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- healthcare
- public health
- randomized controlled trial
- emergency department
- physical activity
- depressive symptoms
- social media
- climate change
- sleep quality
- health promotion
- cerebral ischemia